ReviewCancer immunology, immunotherapy : CII2007
Tumor escape mechanisms in prostate cancer.
Review in Cancer immunology, immunotherapy : CII, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 83 citations in OpenAlex.
- Article
- Arginine and Arginases Modulate Metabolism, Tumor Microenvironment and Prostate Cancer Progression.Nutrients · 2021Review
- Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.Prostate cancer and prostatic diseases · 2021Article
- Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.Journal of personalized medicine · 2021Review
- Lipid Metabolism in Tumor-Infiltrating T Cells.Advances in experimental medicine and biology · 2021Article
- FOXP3The Prostate · 2018Article
- Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.Cancers · 2017Review
- Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions.Scientific reports · 2015Article
- CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.Cancer research · 2015Article
- Article
- Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14Oncoimmunology · 2014Article
- From bench to bedside: immunotherapy for prostate cancer.BioMed research international · 2014Review
- Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.Frontiers in immunology · 2014Review
- Immunotherapy and immune evasion in prostate cancer.Cancers · 2013Article
- Demethylation of cancer/testis antigens and CpG ODN stimulation enhance dendritic cell and cytotoxic T lymphocyte function in a mouse mammary model.BioMed research international · 2013Article
- DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?Genetic vaccines and therapy · 2012Article
- Cancer immunotherapy: a paradigm shift for prostate cancer treatment.Nature reviews. Urology · 2012Review
- Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy.Cancer immunology, immunotherapy : CII · 2012Review
- Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer.Journal of translational medicine · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous immunotherapy trials have been carried out in prostate cancer (PC) patients, with induction of antigen-specific T cells in some cases. Despite this capability, limited success is seen in terms of tumor regression or survival. In this review, we discuss the evidence for tumor escape strategies that may contribute to vaccine failure in the setting of PC. These include defects in antigen presentation, production of immunosuppressive substances, induction of T cell death, T cell receptor dysfunction, and the presence of tolerogenic dendritic cells and regulatory T cells inside prostate tumors. It is clear that novel strategies aimed at preventing tumor escape, such as small molecular weight inhibitors of immunosuppressive molecules, adoptive transfer of TCR transgenic T cells, removal of Tregs, combined with anti-androgen therapy and prostate-specific vaccines, need to be examined further in PC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.